GlassScriptPhysician profile
Anthony M Young
NPI 1255596060
$2,325.18
in general payments reported to CMS, 2019-2025
35 companies · $38.13 in 2025
The $38.13 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $938 · 2022: $959 · 2023: $304 · 2024: $86.67 · 2025: $38.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $379.53 | 2021-2023 | |
| Novo Nordisk INC | $174.82 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $149.55 | 2021-2025 | |
| Boston Scientific Corporation | $131.52 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.11 | 2021-2022 | |
| Glaxosmithkline, LLC. | $123.88 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $104.21 | 2021-2023 | |
| Amgen INC. | $102.66 | 2021-2022 | |
| Abbott Laboratories | $102.54 | 2022-2023 | Freestyle Libre 3 |
| Genentech USA, INC. | $86.67 | 2024 | Xolair |
| Astellas Pharma US INC | $80.39 | 2021 | |
| Sanofi-Aventis U.S. LLC | $72.49 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $68.14 | 2021-2022 | |
| Amarin Pharma, INC. | $60.58 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $55.39 | 2021-2023 | Livalo, Seglentis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $51.12 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $48.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.28 | 2021-2022 | |
| Mylan Specialty L.P. | $39.35 | 2021 | |
| Eisai INC. | $37.61 | 2021 | |
| Esperion Therapeutics, INC. | $37.34 | 2021 | |
| Smith+Nephew, INC. | $26.73 | 2021 | |
| Merck Sharp & Dohme LLC | $25.33 | 2021-2022 | |
| Sanofi Pasteur INC. | $23.29 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $22.57 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.41 | 2021 | |
| Edwards Lifesciences Corporation | $17.47 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.40 | 2022 | |
| Exact Sciences Corporation | $15.26 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $14.65 | 2023 | Gemtesa |
| Horizon Therapeutics Plc | $14.12 | 2021 | |
| Lucid Diagnostics INC. | $13.91 | 2022 | |
| Medtronic, INC. | $12.83 | 2023 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.